259793-96-9 cas favipiravir avigan

favipiravir, a new broad-spectrum antiviral drug developed by Toyama Chemical Pharmaceuticals of Japan to target RNA-dependent RNA polymerase (RdRp), was approved in Japan in March 2014 for the treatment of new and compound hairdressing influenza. During the outbreak of the new coronavirus, the results of a Phase I clinical study of the drug, which was made public in March 2020, showed that the drug showed the potential for progression in relieving new coronavirus pneumonia by accelerating the removal of the virus.

Fapiravi can be used for antiviral treatment of influenza A and B. Studies have shown that, in addition to influenza viruses, the drug also shows good antiviral activity against a variety of RNA viruses, such as Ebola virus, sand granulated virus, Bunia virus, rabies virus and so on.

WHY CHOOSE US

1. Quality

Our products meet MSDS safe standard and we have ISO and other certificate so yan can get high quality products from our company.

2. Price

We are the company which is the joint of trade and industry so we cao provide the competitive price and high quality product.

3. Packing

We can do according to the customers' request.

4. Transport

The products can be transported by DHL, FEDEX, TNT, EMS, EUB, by air and by sea.

5. Service

We offer specialized logistic service including export declaration,customs clearance and every detail during shipment,this makes us able to offer you one-stop service from the order to the products transported to your hand.

OUR TEAM

We are professional team.We insist the high product,we believe nothing is impossible.If we always do best,we will succeed.the clients will select our product.Known for its best quality and competitve price, this chemicals we offered is widely appreciated by our customers.